Treatment of nail psoriasis: common concepts and new trends

Yasemin Oram, A Deniz Akkaya, Yasemin Oram, A Deniz Akkaya

Abstract

The lifetime incidence of nail involvement in psoriatic patients is estimated to be 80-90%, and the nails can be affected in 10% to 55% of psoriatic patients. Psoriasis may also solely involve the nails, without any other skin findings, in which the treatment can be more challenging. Nail psoriasis may lead to considerable impairment in quality of life due to aesthetic concerns and more importantly limitations in daily activities resulting from the associated pain, which may be overlooked by the physicians. Several topical and systemic treatment modalities, as well as radiation and light systems, have been used in the treatment of nail psoriasis. In the last decade, the introduction of biologic agents and the utilization of laser systems have brought a new insight into the treatment of nail psoriasis. This paper focuses on the recent advances, as well as the conventional methods, in treating nail psoriasis in adults and children, in reference to an extensive literature search.

References

    1. Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. Journal of the American Academy of Dermatology. 2007;57(1):1–27.
    1. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology. 2008;216(4):366–372.
    1. Armesto S, Esteve A, Coto-Segura P, et al. Nail psoriasis in individuals with psoriasis vulgaris: a study of 661 patients. Actas Dermo-Sifiliograficas. 2011;102(5):365–372.
    1. Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clinics in Dermatology. 2008;26(5):448–459.
    1. Hallaji Z, Babaeijandaghi F, Akbarzadeh M, et al. A significant association exists between the severity of nail and skin involvement in psoriasis. Journal of the American Academy of Dermatology. 2012;66:e12–e13.
    1. Augustin M, Reich K, Blome C, Schäfer I, Laass A, Radtke MA. Nail psoriasis in Germany: epidemiology and burden of disease. British Journal of Dermatology. 2010;163(3):580–585.
    1. Dehesa L, Tosti A. Treatment of inflammatory nail disorders. Dermatology and Therapy. 2012;25:525–534.
    1. Tan ES, Chong WS, Tey HL. Nail psoriasis: a review. American Journal of Clinical Dermatology. 2012;13:375–388.
    1. de Berker D. Management of psoriatic nail disease. Seminars in Cutaneous Medicine and Surgery. 2009;28(1):39–43.
    1. Gupta AK, Lynde CW, Jain HC, et al. A higher prevalence of onychomycosis in psoriatics compared with non- psoriatics: a multicentre study. British Journal of Dermatology. 1997;136(5):786–789.
    1. Maejima H, Taniguchi T, Watarai A, Katsuoka K. Evaluation of nail disease in psoriatic arthritis by using a modified nail psoriasis severity score index. International Journal of Dermatology. 2010;49(8):901–906.
    1. Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI) Arthritis Care & Research. 2011;63:S64–S85.
    1. Rich P, Scher RK. Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. Journal of the American Academy of Dermatology. 2003;49(2):206–212.
    1. Mukai MM, Poffo IF, Werner B, Brenner FM, Lima Filho JH. NAPSI utilization as an evaluation method of nail psoriasis in patients using acitretin. Anais Brasileiros de Dermatologia e Sifilografia. 2012;87:256–262.
    1. Cassell SE, Bieber JD, Rich P, et al. The modified nail psoriasis severity index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. Journal of Rheumatology. 2007;34(1):123–129.
    1. de Vries AC, Bogaards NA, Hooft L, et al. Interventions for nail psoriasis. The Cochrane Database of Systematic Reviews. 2013;1CD007633
    1. Nakamura RC, Abreu LD, Duque-Estrada B, Tamler C, Leverone AP. Comparison of nail lacquer clobetasol efficacy at 0.05%, 1% and 8% in nail psoriasis treatment: prospective, controlled and randomized pilot study. Anais Brasileiros de Dermatologia e Sifilografia. 2012;87:203–211.
    1. Fischer-Levancini C, Sánchez-Regaña M, Llambí F, Collgros H, Expósito-Serrano V, Umbert-Millet P. Nail psoriasis: treatment with tazarotene 0.1% hydrophilic ointment. Actas Dermo-Sifiliográficas. 2012;103:725–728.
    1. De Simone C, Maiorino A, Tassone F, D'Agostino M, Caldarola G. Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study. Journal of the European Academy of Dermatology and Venereology. 2012
    1. Tzung TY, Chen CY, Yang CY, Lo PY, Chen YH. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Dermato-Venereologica. 2008;88(3):279–280.
    1. Sánchez Regaña M, Márquez Balbás G, Umbert Millet P. Nail psoriasis: a combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment. Journal of the European Academy of Dermatology and Venereology. 2008;22(8):963–969.
    1. Rigopoulos D, Gregoriou S, Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study. Acta Dermato-Venereologica. 2007;87(2):167–168.
    1. Regaña MS, Ezquerra GM, Millet PU, Mateos FL. Treatment of nail psoriasis with 8% clobetasol nail lacquer: positive experience in 10 patients. Journal of the European Academy of Dermatology and Venereology. 2005;19(5):573–577.
    1. Cannavò SP, Guarneri F, Vaccaro M, Borgia F, Guarneri B. Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study. Dermatology. 2003;206(2):153–156.
    1. Bianchi L, Soda R, Diluvio L, Chimenti S. Tazarotene 0-1% gel for psoriasis of the fingernails and toenails: an open, prospective study. British Journal of Dermatology. 2003;149(1):207–209.
    1. Rigopoulos D, Ioannides D, Prastitis N, Katsambas A. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Dermato-Venereologica. 2002;82(2):p. 140.
    1. Scher RK, Stiller M, Isabel Zhu Y. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis. 2001;68(5):355–358.
    1. de Jong EMGJ, Menke HE, Van Praag MCG, Van De Kerkhof PCM. Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: a double-blind study. Dermatology. 1999;199(4):313–318.
    1. Baran R, Tosti A. Topical treatment of nail psoriasis with a new corticoid-containing nail lacquer formulation. Journal of Dermatological Treatment. 1999;10(3):201–204.
    1. Tosti A, Piraccini BM, Cameli N, et al. Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. British Journal of Dermatology. 1998;139(4):655–659.
    1. Yamamoto T, Katayama I, Nishioka K. Topical anthralin therapy for refractory nail psoriasis. Journal of Dermatology. 1998;25(4):231–233.
    1. Fredriksson T. Topically applied fluorouracil in the treatment of psoriatic nails. Archives of Dermatology. 1974;110(5):735–736.
    1. Usmani N, Wilson C. A case of nail psoriasis treated with topical calcitriol. Clinical and Experimental Dermatology. 2006;31(5):712–713.
    1. Rigopoulos D, Gregoriou S, Belyayeva E, Larios G, Kontochristopoulos G, Katsambas A. Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study. British Journal of Dermatology. 2009;160(4):858–860.
    1. Prins AMA, Vos K, Franssen EJF. Instability of topical ciclosporin emulsion for nail psoriasis. Dermatology. 2007;215(4):362–363.
    1. Bleeker JJ. Intralesional triamcinolone acetonide using the Port O Jet and needle injections in localized dermatoses. British Journal of Dermatology. 1974;91(1):97–101.
    1. Saricaoglu H, Oz A, Turan H. Nail psoriasis successfully treated with intralesional methotrexate: case report. Dermatology. 2011;222(1):5–7.
    1. Marx JL, Scher RK. Response of psoriatic nails to oral photochemotherapy. Archives of Dermatology. 1980;116(9):1023–1024.
    1. Stern DK, Creasey AA, Quijije J, Lebwohl MG. UV-A and UV-B penetration of normal human cadaveric fingernail plate. Archives of Dermatology. 2011;147(4):439–441.
    1. Rados J, Dobrić I, Pasić A, Lipozencić J, Ledić-Drvar D, Stajminger G. Normalization in the appearance of severly damaged psoriatic nails using soft x-rays. A case report. Acta Dermatovenerologica Croatica. 2007;15:27–32.
    1. Oram Y, Karincaòlu Y, Koyuncu E, Kaharaman F. Pulsed dye laser in the treatment of nail psoriasis. Dermatologic Surgery. 2010;36(3):377–381.
    1. Treewittayapoom C, Singvahanont P, Chanprapaph K, Haneke E. The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: a randomized, double-blind, intrapatient left-to-right study. Journal of the American Academy of Dermatology. 2012;66:807–812.
    1. Fernández-Guarino M, Harto A, Sánchez-Ronco M, García-Morales I, Jaén P. Pulsed dye laser vs. photodynamic therapy in the treatment of refractory nail psoriasis: a comparative pilot study. Journal of the European Academy of Dermatology and Venereology. 2009;23(8):891–895.
    1. Sánchez-Regaña M, Sola-Ortigosa J, Alsina-Gibert M, Vidal-Fernández M, Umbert-Millet P. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy) Journal of the European Academy of Dermatology and Venereology. 2011;25(5):579–588.
    1. Gümüşel M, Özdemir M, Mevlitoğlu I, Bodur S. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. Journal of the European Academy of Dermatology and Venereology. 2011;25:1080–1084.
    1. Tosti A, Ricotti C, Romanelli P, Cameli N, Piraccini BM. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Archives of Dermatology. 2009;145(3):269–271.
    1. Syuto T, Abe M, Ishibuchi H, Ishikawa O. Successful treatment of psoriatic nails with low-dose cyclosporine administration. European Journal of Dermatology. 2007;17(3):248–249.
    1. Feliciani C, Zampetti A, Forleo P, et al. Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol. Journal of Cutaneous Medicine and Surgery. 2004;8(2):122–125.
    1. Mahrle G, Schulze HJ, Färber L, Weidinger G, Steigleder GK. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. Journal of the American Academy of Dermatology. 1995;32:78–88.
    1. Ricceri F, Pescitelli L, Tripo L, Bassi A, Prignano F. Treatment of severe nail psoriasis with acitretin: an impressive therapeutic result. Dermatology and Therapy. 2013;26:77–78.
    1. Handa S. Newer trends in the management of psoriasis at difficult to treat locations: scalp, palmoplantar disease and nails. Indian Journal of Dermatology, Venereology and Leprology. 2010;76(6):634–644.
    1. Langley RG, Saurat JH, Reich K. Nail Psoriasis Delphi Expert Panel. Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus. Journal of the European Academy of Dermatology and Venereology. 2012;26:373–381.
    1. Bianchi L, Bergamin A, De Felice C, Capriotti E, Chimenti S. Remission and time of resolution of nail psoriasis during infliximab therapy. Journal of the American Academy of Dermatology. 2005;52(4):736–737.
    1. Rich P, Griffiths CEM, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. Journal of the American Academy of Dermatology. 2008;58(2):224–231.
    1. Fabroni C, Gori A, Troiano M, Prignano F, Lotti T. Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients. Journal of the European Academy of Dermatology and Venereology. 2011;25(5):549–553.
    1. Rigopoulos D, Gregoriou S, Stratigos A, et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. British Journal of Dermatology. 2008;159(2):453–456.
    1. Leonardi C, Langley RG, Papp K, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Archives of Dermatology. 2011;147(4):429–436.
    1. Van den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Annals of the Rheumatic Diseases. 2010;69(2):394–399.
    1. Rigopoulos D, Gregoriou S, Lazaridou E, et al. Treatment of nail psoriasis with adalimumab: an open label unblinded study. Journal of the European Academy of Dermatology and Venereology. 2010;24(5):530–534.
    1. Ortonne JP, Paul C, Berardesca E, et al. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. The British Journal of Dermatology. 2012
    1. Luger TA, Barker J, Lambert J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. Journal of the European Academy of Dermatology and Venereology. 2009;23(8):896–904.
    1. Kavanaugh A, Mclnnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis and Rheumatism. 2009;60(4):976–986.
    1. Körver JEM, Langewouters AMG, Van De Kerkhof PCM, Pasch MC. Therapeutic effects of a 12-week course of alefacept on nail psoriasis. Journal of the European Academy of Dermatology and Venereology. 2006;20(10):1252–1255.
    1. Parrish CA, Sobera JO, Robbins CM, Cantrell WC, Desmond RA, Elewski BE. Alefacept in the treatment of psoriatic nail disease: a proof of concept study. Journal of drugs in dermatology. 2006;5(4):339–340.
    1. Cassetty CT, Alexis AF, Shupack JL, Strober BE. Alefacept in the treatment of psoriatic nail disease: a small case series. Journal of the American Academy of Dermatology. 2005;52(6):1101–1102.
    1. Patsatsi A, Kyriakou A, Sotiriadis D. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study. Journal of Dermatological Treatment. 2013;24:96–100.
    1. Vitiello M, Tosti A, Abuchar A, Zaiac M, Kerdel FA. Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients. International Journal of Dermatology. 2013;52:358–362.
    1. Igarashi A, Kato T, Kato M, Song M, Nakagawa H. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. Journal of Dermatology. 2012;39:242–252.
    1. Reich K, Langley RG, Papp KA, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. The New England Journal of Medicine. 2011;365:1586–1596.
    1. Reich K, Ortonne JP, Kerkmann U, et al. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS trial. Dermatology. 2010;221(2):172–178.
    1. Hussain W, Coulson I, Owen C. Severe recalcitrant nail psoriasis responding dramatically to infliximab: report of two patients. Clinical and Experimental Dermatology. 2008;33(4):520–522.
    1. Rallis E, Stavropoulou E, Rigopoulos D, Verros C. Rapid response of nail psoriasis to etanercept. Journal of Rheumatology. 2008;35(3):544–545.
    1. Coelho JD, Diamantino F, Lestre S, Ferreira AM. Treatment of severe nail psoriasis with etanercept. Indian Journal of Dermatology, Venereology and Leprology. 2011;77(1):72–74.
    1. Gómez Vázquez M, Navarra Amayuelas R. Marked improvement in nail psoriasis during treatment with etanercept. Dermatology and Therapy. 2011;24:498–500.
    1. Zaiac M. The role of biological agents in the treatment of nail psoriasis. American Journal of Clinical Dermatology. 2010;11(1):27–29.
    1. Puig L, Morales-Múnera CE, López-Ferrer A, Geli C. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. Dermatology. 2012;225:14–17.
    1. Hermanns-Lê T, Berardesca E, Piérard GE, Lesuisse M, Piérard-Franchimont C. Challenging regional psoriasis and ustekinumab biotherapy: impact of the patterns of disease. Journal of Biomedicine and Biotechnology. 2012;2012:6 pages.413767
    1. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. The New England Journal of Medicine. 2012;366:1190–1199.
    1. Mercy K, Kwasny M, Cordoro KM, et al. Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States. Pediatric Dermatology. 2013
    1. Al-Mutairi N, Manchanda Y, Nour-Eldin O. Nail changes in childhood psoriasis: a study from Kuwait. Pediatric Dermatology. 2007;24(1):7–10.
    1. Ståhle M, Atakan N, Boehncke WH, et al. Juvenile psoriasis and its clinical management: a European expert group consensus. Journal of the German Society of Dermatology. 2010;8(10):812–819.
    1. Seyhan M, Coşkun BK, Sağlam H, Özcan H, Karincaoğlu Y. Psoriasis in childhood and adolescence: evaluation of demographic and clinical features. Pediatrics International. 2006;48(6):525–530.
    1. Khoo BP, Giam YC. A pilot study on the role of intralesional triamcinolone acetonide in the treatment of pitted nails in children. Singapore Medical Journal. 2000;41(2):66–68.
    1. Diluvio L, Campione E, Paternò EJ, Mordenti C, Hachem ME, Chimenti S. Childhood nail psoriasis: a useful treatment with tazarotene 0.05% Pediatric Dermatology. 2007;24(3):332–333.
    1. Liang CY, Lin TY, Lin YK. Successful treatment of pediatric nail psoriasis with periodic pustular eruption using topical indigo naturalis oil extract. Pediatric Dermatology. 2013;30:117–119.
    1. Kiszewski AE, De Villa D, Scheibel I, Ricachnevsky N. An infant with acrodermatitis continua of hallopeau: successful treatment with thalidomide and UVB therapy. Pediatric Dermatology. 2009;26(1):105–106.
    1. Richert B, André J. Nail disorders in children: diagnosis and management. American Journal of Clinical Dermatology. 2011;12(2):101–112.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa